open access

Vol 3, No 6 (2007)
Review paper
Published online: 2008-05-08
Get Citation

Targeted therapy of colorectal cancer patients

Marek Z. Wojtukiewicz, Ewa Sierko
Onkol. Prak. Klin 2007;3(6):286-297.

open access

Vol 3, No 6 (2007)
REVIEW ARTICLES
Published online: 2008-05-08

Abstract

Colorectal cancer is one of the most frequently diagnosed malignant neoplasms in humans. Recently, introduction of targeted therapy resulted in improved results of the treatment in the group of cancer patients. To date, agents interfering with angiogenesis and with the activity of epidermal growth factor receptor (EGFR) are the most often tested in clinical trials. In the article biological basis of such therapy and results of clinical trials on the efficacy of monoclonal antibodies (mAbs) directed to the most important proangiogenic factor - VEGF and mAbs against EGFR are summarized. As for now, the mAbs are already approved for the treatment of advanced colorectal cancer patients. Other options of new vessel formation inhibition (eg. interfering with activity of VEGF receptor), a rationale for and efficacy of various forms of targeted therapy combination (eg. inhibiting of both VEGF and EGFR activity) as well as combination of targeted treatment with cytotoxic therapy and/or radiation therapy are also discussed. Ongoing clinical trials on the novel forms of treatment of colorectal cancer patients in adjuvant and palliative settings are presented in the article.

Abstract

Colorectal cancer is one of the most frequently diagnosed malignant neoplasms in humans. Recently, introduction of targeted therapy resulted in improved results of the treatment in the group of cancer patients. To date, agents interfering with angiogenesis and with the activity of epidermal growth factor receptor (EGFR) are the most often tested in clinical trials. In the article biological basis of such therapy and results of clinical trials on the efficacy of monoclonal antibodies (mAbs) directed to the most important proangiogenic factor - VEGF and mAbs against EGFR are summarized. As for now, the mAbs are already approved for the treatment of advanced colorectal cancer patients. Other options of new vessel formation inhibition (eg. interfering with activity of VEGF receptor), a rationale for and efficacy of various forms of targeted therapy combination (eg. inhibiting of both VEGF and EGFR activity) as well as combination of targeted treatment with cytotoxic therapy and/or radiation therapy are also discussed. Ongoing clinical trials on the novel forms of treatment of colorectal cancer patients in adjuvant and palliative settings are presented in the article.
Get Citation

Keywords

colorectal cancer; targeted therapy; bevacizumab; cetuximab

About this article
Title

Targeted therapy of colorectal cancer patients

Journal

Oncology in Clinical Practice

Issue

Vol 3, No 6 (2007)

Article type

Review paper

Pages

286-297

Published online

2008-05-08

Bibliographic record

Onkol. Prak. Klin 2007;3(6):286-297.

Keywords

colorectal cancer
targeted therapy
bevacizumab
cetuximab

Authors

Marek Z. Wojtukiewicz
Ewa Sierko

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl